1. Sonnenwirth AC, Jarett L, Gradwohl's Clinical Laboratory Methods and Diagnosis, 8thed, Missouri, The C.V. Mosby Company,1980: Volume one, Chapter 15: 305-306.

2. Burtis CA, Bruns DE. Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics. 17th edition. ELSEVIER Publication. 2015. Chapter 19: 323.

3. Harcke SJ, Rizzolo D, Harcke HT. G6PD deficiency: An update. JAAPA. 2019. 32(11):21-26. [DOI:10.1097/01.JAA.0000586304.65429.a7] [PMID]

4. Moriyama T, Tamura S, Nakano K, Otsuka K, Shigemura M, Honma N. Laboratory and clinical features of abnormal macroenzymes found in human sera. Biochim Biophys Acta. 2015; 1854(6):658-67. [DOI:10.1016/j.bbapap.2014.10.015] [PMID]

5. Catassi C, Verdu EF, Bai JC, Lionetti E. Coeliac disease. Lancet. 2022. 25;399(10344):2413-2426. [DOI:10.1016/S0140-6736(22)00794-2] [PMID]

6. Rayman MP. Multiple nutritional factors and thyroid disease, with particular reference to autoimmune thyroid disease. Proc Nutr Soc. 2019; 78(1):34-44. [DOI:10.1017/S0029665118001192] [PMID]

7. Hamidi Nokhostin K. MAPK superfamily enzymes and their relation to cancer and clinical laboratory. The 12th International Congress on Quality Improvement in Clinical Laboratories, 2019.

8. HamidiNokhostin K, Zahri S, Latifi Navid S, Hasanpour F, Tamouk L, JNK (A kind of MAPK Enzyme) gene expression and its level in stomach and breast cancer cell lines under abiotic stresses: results of two research projects. The 12th International Congress on Quality Improvement in Clinical Laboratories, 2019.

9. Hasanpour F, Hamidi Nokhostin K, Zahri S, LatifiNavid S. Study of cell viability and JNK/SAPK level following abiotic stresses (Heat & Radiation) in breast cancer cells. J Ardabil Univ Med Sci. 2017; 17(2):154-163. [Full text in Persian]

10. Shiffman M, Freilich B, Vuppalanchi R, Watt K, Chan JL, Spada A, et al .Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2019;49(1):64-73. [DOI:10.1111/apt.15030] [PMID] []

11. Karimzadeh Shushbolagh N, Mansour Kiaie S, Hamidi Nokhostin K. Hemoglobin removal by zinc sulfate to assay level and activity of red blood cell caspase-3 using ELISA and colorimetric methods. J Ardabil Univ Med Sci. 2023; 23(1):82-90. [Full text in Persian] [DOI:10.61186/jarums.23.1.82]

12. Hamidi Nokhostin K, Kasaei Kivi SH, Safari Ezmare Sofla M. The effect of hypertonic stress and its duration on the level and activity of executioner caspase enzymes in blood anuclear cells (Platelets). Jentashapir J Cell Mol Biol. 2024; 15(2):e145467. [DOI:10.5812/jjcmb-145467]

13. Jurisic V, Radenkovic S, Konjevic G. The Actual Role of LDH as Tumor Marker, Biochemical and Clinical Aspects. Adv Exp Med Biol. 2015;867:115-24. [DOI:10.1007/978-94-017-7215-0_8] [PMID]

14. Zhang J, Zhang L, Pan S, Gu B, Zhen Y, Yan J, et al . Amylase: sensitive tumor marker for amylase-producing lung adenocarcinoma. J Thorac Dis. 2013;5(4):E167-9.

15. Anamthathmakula P, Erickson JA, Winuthayanon W. Blocking serine protease activity prevents semenogelin degradation leading to hyperviscous semen in humans. Biol Reprod. 2022; 106(5):879-887. [DOI:10.1093/biolre/ioac023] [PMID] []

16. Alakbarzade V, O'Kane D, Pereira AC. Hypersensitivity reactions to recombinant tissue plasminogen activator. Pract Neurol. 2020; 20(1):75-79.

17. Vellard M. The enzyme as drug: application of enzymes as pharmaceuticals. Curr Opin Biotechnol. 2003; 14(4):444-50. [DOI:10.1016/S0958-1669(03)00092-2] [PMID]

18. De la Fuente M, Lombardero L, Gomez- Gonzalez A, Solari C, Angulo Barturen I, Acera A, et al. Enzyme Therapy: Current challenges and future perspectives. Int J Mol Sci. 2021. 22(17):9181. [DOI:10.3390/ijms22179181] [PMID] []

19. Wójcik T, Kieć-Kononowicz K. Catalytic activity of certain antibodies as a potential tool for drug synthesis and for directed prodrug therapies. Curr Med Chem. 2008; 15(16):1606-15. [DOI:10.2174/092986708784911533] [PMID]

20. Vickneson K, George J. Xanthine Oxidoreductase Inhibitors. Handb Exp Pharmacol. 2021; 264:205-228. [DOI:10.1007/164_2020_383] [PMID]

21. Polakovičová M, Jampílek J. Advances in structural biology of ACE and development of domain selective ACE-inhibitors. Med Chem. 2019; 15(6):574-587. [DOI:10.2174/1573406415666190514081132] [PMID]

22. Bicket DP. Using ACE inhibitors appropriately. Am Fam Physician. 2002; 66(3):461-8.

23. Cui J, Jia J. Natural COX-2 inhibitors as promising anti-inflammatory agents: an update. Curr Med Chem. 2021; 28(18):3622-46. [DOI:10.2174/0929867327999200917150939] [PMID]

24. Balasubramanian R, Maideen NMP. HMG-CoA reductase inhibitors (statins) and their drug interactions involving CYP enzymes, P-glycoprotein and OATP transporters-an overview. Curr Drug Metab. 2021; 22(5):328-41. https://doi.org/10.2174/18755453MTEz9MzEj5 [DOI:10.2174/1389200222666210114122729]

25. Orhan IE. Enzyme inhibitors as the attractive targets for the treatment of various diseases. Curr Med Chem. 2019; 26(18):3206-07. [DOI:10.2174/092986732618190821115641] [PMID]

26. Hoffmann VS, Hasford J, Deininger M, Cortes J, Baccarani M, Hehlmann R. Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia. J Cancer Res Clin Oncol. 2017; 143(7):1311-18. [DOI:10.1007/s00432-017-2385-7] [PMID]

27. Araki T, Hamada K, Myat AB, Ogino H, Hayashi K, Maeda M, et al. Enhanced cytotoxicity on cancer cells by combinational treatment of PARP inhibitor and 5-Azadeoxycytidine accompanying distinct transcriptional profiles. Cancers (Basel). 2022; 14(17):4171. [DOI:10.3390/cancers14174171] [PMID] []

28. Nelsohn DL, Cox MM. Lehninger's Principles of Biochemistry. 7th ed. W.H. Freeman company. 2017. Chapter 6: 207-208.

29. Nader Rifai, Chiu RWK, Young I, Burnnam CAD, Wittwer CT. Tietz Textbook of Laboratory Medicine. Elsevier Co. 7th ed. 2023.Chapter 50: 695.

30. Tille PM. Bailey and Scotts Diagnostic Microbiology. 13th ed. Mosby Inc.2014. Chapter 7: 97-99.

31. Larkins MC, Thombare A. Point-of-Care Testing. 2023 May 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. PMID: 37276307.

32. Nagaraja P, Krishna H, Shivakumar A, Shrestha AK. Development of quantitative enzymatic method and its validation for the assay of glucose in human serum. Clin Biochem. 2012; 45(1-2):139-43. [DOI:10.1016/j.clinbiochem.2011.11.007] [PMID]

33. Jones KS, Parkington DA, Cox LJ, Koulman A. Erythrocyte transketolase activity coefficient (ETKAC) assay protocol for the assessment of thiamine status. Ann N Y Acad Sci. 2021; 1498(1):77-84. [DOI:10.1111/nyas.14547] [PMID] []

34. Tabatabaei MS, Ahmed M. Enzyme-Linked Immunosorbent Assay (ELISA). Methods Mol Biol. 2022; 2508:115-134. [DOI:10.1007/978-1-0716-2376-3_10] [PMID]

35. Liu Z, Gurlo T, von Grafenstein H. Cell-ELISA using beta-galactosidase conjugated antibodies. J Immunol Methods. 2000; 234(1-2):P153-67. [DOI:10.1016/S0022-1759(99)00216-1] [PMID]

36. Jin H, Yang PB, Feng GF, Jia N, Yang WN, Wang WX. [Optimization of trypsin digestion intensity to obtain high-purity in vitro cultured astrocytes]. Sheng Li Xue Bao. 2015; 67(1):103-9. [Full text in Chinese]

37. Raina A, Dogra TD. Application of DNA fingerprinting in medicolegal practice. J Indian Med Assoc. 2002; 100(12):688-94.

38. Hamidi Nokhostin K. Human erythrocyte peroxiredoxin II and its interaction with thioredoxin, sulfiredoxin and mitogen activated protein kinase dissertation, University of Exeter, UK. 2009

39. Panina Y, Germond A, Masui S, Watanabe TM. Validation of common housekeeping genes as reference for qPCRgene expression analysis during iPS reprogramming process. Sci Rep. 2018; 8(1):8716. [DOI:10.1038/s41598-018-26707-8] [PMID] []

40. Jenny RJ, Mann KG, Lundblad RL. A critical review of the methods for cleavage of fusion proteins with thrombin and factor Xa. Protein Expr Purif. 2003; 31(1):1-11. [DOI:10.1016/S1046-5928(03)00168-2] [PMID]

41. Kennelly PJ, Botham KM, McGuinness O, Rodwell VW, Weil PA. Harper's Illustrated Biochemistry. McGraw Hill. 32nd ed. 2023. Chapter 41: 490-491.

42. Catanzaro R, Sciuto M, Marotta F. Lactose intolerance: An update on its pathogenesis, diagnosis, and treatment. Nutr Res. 2021; 89:23-34. [DOI:10.1016/j.nutres.2021.02.003] [PMID]

43. Patry J, Blanchette V. Enzymatic debridement with collagenase in wounds and ulcers: a systematic review and meta-analysis. Int Wound J. 2017; 14(6):1055-65. [DOI:10.1111/iwj.12760] [PMID] []

44. Razzaq A, Shamsi S, Ali A, Ali Q, Sajjad M, Malik A, et al. Microbial proteases applications. Front Bioeng Biotechnol. 2019. 12; 7:110. [DOI:10.3389/fbioe.2019.00110] [PMID] []

45. Hwang HG, Kim KJ, Lee SH, Kim CK, Min CK, Yun JM, et al. Recombinant glargine insulin production process using Escherichia coli. J Microbiol Biotechnol. 2016; 26(10):1781-9. [DOI:10.4014/jmb.1602.02053] [PMID]

46. Ornla-Ied P, Sonwai S, Lertthirasuntorn S. Trans-free margarine fat produced using enzymatic interesterification of rice bran oil and hard palm stearin. Food Sci Biotechnol. 2016. 30;25(3):673-680. [DOI:10.1007/s10068-016-0118-3] [PMID] []